Summary of "Trenbolone WITHOUT Side-Effects, IM Vs. SubQ Debate, Methylene Blue & SLU-PP-332 Revisited"

Summary — key points and takeaways

Repeated theme: many interventions are individual — experiment cautiously, get bloodwork, and don’t blindly copy someone else’s protocol.

General

This episode of the Anabolic Round Table revisited several hot topics: SLU‑PP‑332 and methylene blue (effects, dosing, stacking), trenbolone side‑effects and mitigation strategies, pros/cons of subcutaneous (SubQ) vs intramuscular (IM) injections, and a brief discussion of appetite/fat‑loss compounds (tesofensine, semaglutide) and other biohacks.
Emphasis throughout: individual responses vary. Start low, monitor with labs, and be cautious when combining compounds.

Methylene blue + SLU‑PP‑332

Reported effects

Methylene blue (MB)
- Anecdotal benefits: improved energy, mood, mitochondrial oxygen utilization, and reduced SSRI withdrawal/“brain zaps” for some users.
- Important safety note: MB inhibits monoamine oxidase (MAO) — potential for drug interactions with serotonergic/adrenergic agents.
SLU‑PP‑332 (novel compound)
- From anecdotes and preclinical data: increased mitochondrial biogenesis, increased fatty‑acid oxidation, improved insulin sensitivity/glucose handling, prevention of fat gain in high‑fat models, improved body composition and perceived energy.
- Reported side effects: increased sweating/clamminess and elevated body temperature.

Dosing & safety

Commonly reported human dose: ~400 mcg/day (some experimenters go to 600–700 mcg/day). 400 mcg was described as a practical “sweet spot.”
Safety data are limited. Early user bloodwork often looks benign (liver enzymes, lipids) but evidence is anecdotal (n=1); more data needed.

Stacking & practical notes

Users reported synergy when combining MB + SLU (enhanced energy/mitochondrial effects).
5‑Amino‑1‑MQ (5‑1MQ) was suggested by some to further promote fat‑loss mechanisms (inhibits NAD+ methylation) — limited evidence and higher cost.
Practical considerations:
- Hydrate and be cautious training in hot or poorly ventilated environments (increased sweating).
- SLU may blunt short‑term fat gain (useful for trips/“eat whatever” windows) but can be costly.
- Consider antioxidant support and lab monitoring (see practical points below).

Tesofensine and appetite agents

Tesofensine: a short‑term appetite suppressant (dopamine/norepinephrine/serotonin reuptake inhibitor).
- Used effectively for short fasts (2–4 days) to suppress hunger and preserve mental clarity.
- Recommended as an acute tool when dieting stalls — not for daily chronic use.
Contrast between drug types:
- Acute stimulatory appetite suppressants (e.g., tesofensine) vs chronic incretin/GI agents (GLP‑1 agonists, tirzepatide).
- Match the agent to the problem: appetite control vs metabolic disease management.
Practical suggestion: use appetite agents only when needed, not prophylactically.

SLU, methylene blue & other ancillaries — practical points

Consider combining mitochondrial enhancers with antioxidants (Vitamin C, NAC, glutathione precursors) to mitigate potential increases in oxidative stress.
Cost vs benefit: weigh marginal gains against expense.
Do bloodwork before and during experimentation. Relevant markers:
- Liver enzymes, lipids
- Inflammatory markers (CRP)
- Ferritin and iron studies (transferrin saturation)
- Glucose/insulin markers

Trenbolone: side‑effects and mitigation

Common side effects discussed

Insomnia and night sweats
Anxiety and agitation (“tren rage”)
Cough (tren cough)
Libido changes
Possible neuro concerns (animal amyloid findings mentioned)
Increased sweating, digestive/histamine effects

Dosing philosophies

Higher doses (~100 mg/day acetate in older competitive reports) can maximize anabolic effects but increase side effects.
Low‑dose strategy: some report anti‑catabolic/anabolic benefits with minimal CNS effects at very low doses (example quoted: 25 mg/week subcutaneous). Microdosing can reduce behavioral and sleep disturbances.

Timing & injection technique

Daily small SubQ injections or morning microdosing may reduce sleep disruption by avoiding high CNS exposure near bedtime.
SubQ administration and smaller, more frequent dosing often produce smoother exposure.

Mitigation tactics

Magnesium (glycinate/citrate, etc.) at reasonably high doses: may reduce tremor, anxiety and improve sleep. Some suggest checking alkaline phosphatase (ALP) as a rough marker related to magnesium status.
Split GH dosing (large nocturnal bolus + small morning dose) to aid sleep/recovery when using GH.
Address histamine issues with H2 blockers or DAO supplementation if reflux/acid or histamine symptoms occur.
For tren cough:
- Use bronchodilator inhaler (e.g., albuterol) or avoid IV/venous hits.
- SubQ injections or slower absorption may reduce cough risk.
- For severe cough or suspected pulmonary oil embolism, seek medical evaluation and imaging.
Environmental/sleep hygiene to reduce night sweats: cool bedroom, lightweight bedding, fan, cold shower ~90 minutes before bed, seasonal duvet changes.

Mechanisms and long‑term harms

Biological mechanisms discussed: non‑genomic calcium signaling in the CNS, dopamine effects, androgen/estrogen/progesterone receptor interactions, and dopamine clearance genetics (COMT polymorphisms) affecting tolerance.
Repeated IM oil injections can cause scar tissue, reduced mobility and aesthetic changes. SubQ can reduce intramuscular scarring but may create visible fat pad depots. Treatments (dry‑needling, therapy) can help but may not fully reverse long‑term scarring.

Subcutaneous (SubQ) vs intramuscular (IM) injections

Peptides and GH are typically designed for SubQ (water‑based, diffuse quickly); oil‑based steroid esters were designed/studied IM.
Pros of SubQ for steroids:
- Less muscle scarring
- Easier self‑administration
- Potentially smoother blood levels with frequent small doses
Cons of SubQ:
- Limited practical volume (large volumes form lumps/fat pads)
- Slower/less predictable ester cleavage and blood peaks for oil esters
- Visible fat deposits and cosmetic concerns
Pros of IM:
- Suited to larger doses with established release kinetics
- Deeper injection minimizes local lumps
Cons of IM:
- Repeated IM oil injections risk fibrotic scar tissue, mobility/aesthetic issues
Hybrid approach recommended by some:
- Micro daily SubQ or insulin‑pin dosing for low/moderate protocols
- IM for high‑volume competitive cycles

Underground labs, tren color/oxidation and impurities

Anecdotal link between darker/oxidized tren products and higher incidence of tren cough.
Manufacturing variables that affect product tolerability:
- Oxidation, heating, solvent choice, filtration and finishing steps
- Residual solvents, impurities and crude handling can increase inflammation or adverse reactions
Third‑party Certificates of Analysis (COAs) may confirm the labeled compound but do not always detect heavy metals or all contaminants unless specifically tested.

Other discussion points and practical advice

Some newer or underground steroids (e.g., DHB) are poorly studied and potentially risky — extreme caution advised.
Longevity drugs and blood‑sugar medicines are sometimes used unnecessarily by otherwise healthy people; check labs and medical indications first.
Interpreting ferritin and iron:
- High ferritin can indicate inflammation or tissue iron overload; interpret with CRP, GGT and transferrin saturation.
If you are not a clinician: get bloodwork and expert guidance before using specialty compounds (SLU, tesofensine, 5‑1MQ, etc.).
Suggested future topics from the episode: fertility and testicular health, insulin/blood sugar misuse, deeper dive into mircoron/miricor vs clenbutrol, critique of long‑acting GH analogues.

Bottom line / practical rules of thumb

Start low and go slow; keep doses reasonable and experiment cautiously.
Use bloodwork and marker‑guided decisions rather than following social media trends.
Address foundational items first: sleep, magnesium, nutrition and antioxidant status before layering costly or high‑risk ancillaries.
Be particularly cautious when stacking multiple CNS‑active agents (MAO inhibitors, SSRIs, methylene blue, tesofensine, stimulants, high androgen doses) due to interactions and serotonin/dopamine balance.

Speakers (identified in the episode)

Host / podcast presenter
Kurt Havens
Dr. Dean St. Mart

(Other people were mentioned frequently — Chase Irons, Paul Bernett, Colton, Joel Hansen, Ryan Roth — but the active discussion voices were the host, Kurt Havens and Dr. Dean St. Mart.)